As filed with the Securities and Exchange Commission on March 2, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Revance Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware  
(State or other jurisdiction of  
incorporation
 or organization)  
77-0551645  
(I.R.S. Employer  
Identification No.)
7555 Gateway Boulevard
Newark, California 94560
 
(Address of Principal Executive Offices)
 
94560  
(Zip Code)
_____________________________________
2014 Equity Incentive Plan
2014 Employee Stock Purchase Plan

(Full title of the plan)
_____________________________________
L. Daniel Browne
President and Chief Executive Officer
Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark, California 94560
(Name and address of agent for service)
(510) 742-3400
(Telephone number, including area code, of agent for service)
_____________________________________
Copies to:
Gordon K. Ho
Cooley LLP
3175 Hanover Street
Palo Alto, California 94304
(650) 843-5000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨
Accelerated filer ý
Non-accelerated filer ¨  (Do not check if a smaller reporting company)
Smaller reporting company ¨
Emerging growth company ý
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨





CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
 
Amount
to be
Registered(1)
 
Proposed
Maximum
Offering Price
per Share(2)
 
Proposed
Maximum
Aggregate
Offering Price(2)
 
Amount of
Registration Fee
Common Stock, par value $0.001 per share
 
 
 
 
 
 
 
 
– 2014 Equity Incentive Plan
 
1,460,643
 
$
30.20

 
$
44,111,418.60

 
$
5,491.87

– 2014 Employee Stock Purchase Plan
 
300,000
 
$
30.20

 
$
9,060,000.00

 
$
1,127.97

Total
 
1,760,643
 
$
30.20

 
$
53,171,418.60

 
$
6,619.84

(1)
Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock.
(2)
Estimated in accordance with Rule 457(c) and Rule 457(h) promulgated under the Securities Act solely for the purpose of calculating the registration fee. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Market on February 23, 2018, in accordance with Rule 457(c) of the Securities Act.







EXPLANATORY NOTE
The Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 of the Registrant relating to the same employee and non-employee benefit plans set forth herein are effective.
PART II
INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENT ON FORM S-8
Registrant’s Form S-8 Registration Statements filed with the Securities and Exchange Commission on February 28, 2017 (File No. 333-216342), March 4, 2016 (File No. 333-209949), April 3, 2015 (File No. 333-203235) and February 14, 2014 (File No. 333-193963) relating to the Registrant’s 2014 Equity Incentive Plan and 2014 Employee Stock Purchase Plan are each incorporated by reference herein.
EXHIBITS
The exhibits to this Registration Statement are listed on the Exhibit Index attached hereto and incorporated by reference herein.
 






SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newark, State of California on March 2, 2018.
REVANCE THERAPEUTICS, INC.
 
 
By:
 
/s/ L. Daniel Browne
 
 
L. Daniel Browne
 
 
President and Chief Executive Officer

POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints L. Daniel Browne and Lauren P. Silvernail, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their, his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.
Signature
Title
Date
 
 
 
/s/ L. Daniel Browne
President, Chief Executive
March 2, 2018
L. Daniel Browne
Officer and Director
 
 
(Principal Executive Officer)
 
 
 
 
/s/ Lauren P. Silvernail
Chief Financial Officer and
March 2, 2018
Lauren P. Silvernail
Chief Business Officer
 
 
(Principal Financial and Accounting Officer)
 
 
 
 
/s/ Angus C. Russell
Director, Chairman
March 2, 2018
Angus C. Russell
 
 
 
 
 
/s/ Robert Byrnes
Director
March 2, 2018
Robert Byrnes
 
 
 
 
 
/s/ Mark Foley
Director
March 2, 2018
Mark Foley
 
 
 
 
 
/s/ Phyllis Gardner
Director
March 2, 2018
Phyllis Gardner, M.D.
 
 
 
 
 
/s/ Julian S. Gangolli
Director
March 1, 2018
Julian S. Gangolli
 
 
 
 
 
/s/ Philip J. Vickers
Director
March 1, 2018
Philip J. Vickers, Ph.D.
 
 









EXHIBIT INDEX

Exhibit
Number
 
Exhibit Description
 
Incorporated by Reference to the Company's
 
Filed
Herewith
Form
 
File No.
 
Exhibit No.
 
Filed On
4.1
 
 
8-K
 
001-36297
 
3.1
 
February 11, 2014
 
 
4.2
 
 
S-1
 
333-193154
 
3.4
 
December 31, 2013
 
 
4.3
 
 
S-1/A
 
333-193154
 
4.4
 
February 3, 2014
 
 
  4.4
 
 
S-1
 
333-193154
 
10.5
 
January 27, 2014
 
 
  4.5
 
 
10-K
 
001-36297
 
10.6
 
March 4, 2016
 
 
  4.6
 
 
10-Q
 
001-36297
 
10.3
 
November 10, 2015
 
 
  4.7
 
 
10-K
 
001-36297
 
10.8
 
March 4, 2016
 
 
  4.8
 
 
S-1
 
333-193154
 
10.7
 
January 27, 2014
 
 
  5.1
 
 
 
 
 
 
 
 
 
 
X
  23.1
 
 
 
 
 
 
 
 
 
 
X
  23.2
 
 
 
 
 
 
 
 
 
 
X
  24.1
 
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 



Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Revance Therapeutics Charts.
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Revance Therapeutics Charts.